@article {Rayjnnp-2020-324674, author = {Jason Charles Ray and Mahima Kapoor and Richard J Stark and Shuu-Jiun Wang and Lars Bendtsen and Manjit Matharu and Elspeth Jane Hutton}, title = {Calcitonin gene related peptide in migraine: current therapeutics, future implications and potential off-target effects}, elocation-id = {jnnp-2020-324674}, year = {2021}, doi = {10.1136/jnnp-2020-324674}, publisher = {BMJ Publishing Group Ltd}, abstract = {Migraine is the second largest cause of years lost to disability globally among all diseases, with a worldwide prevalence over 1 billion. Despite the global burden of migraine, few classes of therapeutics have been specifically developed to combat migraine. After 30 years of translational research, calcitonin gene-related peptide (CGRP) inhibitors have emerged as a promising new tool in the prevention of migraine. Like all new therapeutics; however, we have limited real-world experience and CGRP has several known systemic actions that warrant consideration. This article provides a narrative review of the evidence for CGRP antagonists and summarises the known and potential side effects that should be considered.}, issn = {0022-3050}, URL = {https://jnnp.bmj.com/content/early/2021/01/25/jnnp-2020-324674}, eprint = {https://jnnp.bmj.com/content/early/2021/01/25/jnnp-2020-324674.full.pdf}, journal = {Journal of Neurology, Neurosurgery \& Psychiatry} }